Please assess the completion status of the following clinical trial:

Trial Title: Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histopathologically confirmed glioblastoma multiforme~  * WHO grade IV disease~* Must undergo leukapheresis ≤ 4 weeks after definitive resection~* Residual radiographic contrast enhancement on post-resection CT scan or MRI must not exceed 1 cm in diameter in two perpendicular axial planes~  * Patients with evidence of contrast enhancement exceeding 1 cm in diameter in two perpendicular axial planes after radiation will not be a candidate for the vaccine despite being previously enrolled and will be removed from the study and replaced~* No radiographic or cytologic evidence of leptomeningeal or multicentric disease~PATIENT CHARACTERISTICS:~* Karnofsky performance status 80-100%~* Curran Group status I-IV~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No active infection requiring treatment~* No unexplained febrile (\>101.5°F) illness~* No known immunosuppressive disease or known HIV infection~* No unstable or severe intercurrent medical conditions such as severe heart or lung disease~* No allergy to temozolomide (TMZ) or otherwise unable to tolerate TMZ for reasons other than lymphopenia~  * Patients who are found after enrollment to be unable to tolerate TMZ will not be a candidate for the vaccine despite being previously enrolled and will be removed from the study and replaced~* No prior allergic reaction to daclizumab or one of its components~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior daclizumab~* No other prior conventional therapeutic intervention except for steroids, radiation, or temozolomide~* No prior inguinal lymph node dissection, radiosurgery, brachytherapy, or radiolabeled monoclonal antibodies~* No concurrent corticosteroids, with the exception of nasal or inhaled steroids, at a dose above physiologic levels~  * Patients requiring an increase in corticosteroids, with the exception of nasal or inhaled steroids, such that at the time of first vaccination they require a dose above physiologic levels, will be removed from the study and replaced (physiologic dose will be defined as \< 2 mg of dexamethasone/day)~ * Once vaccinations have been initiated, if patients subsequently require increased steroids, they will still be permitted to remain on the study, but every effort will be made to minimize steroid requirements~* No prior allogeneic solid organ transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- CMV pp65-LAMP mRNA-loaded DC vaccination (Type: EXPERIMENTAL): Basiliximab will be safe in combination with CMV pp65-LAMP mRNA-loaded DC vaccination and GM-CSF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete